As cell and gene therapy transitions from clinical innovation to commercial implementation, enabling technologies and global infrastructure are becoming critical differentiators.
At the recent Cell and Gene Therapy 2026 Conference, Drug Discovery & Development (DDD) spoke with Abselion’s Marketing Director, Shi qi An about the company’s latest strategic developments and specialist capabilities supporting advanced therapy innovation.
A key highlight was the launch of Abselion’s new US subsidiary site — a move designed to strengthen regional presence, provide localised technical expertise, and enhance collaboration with North American biotech and pharma partners.
The expansion reflects a broader industry shift towards integrated, globally positioned solutions that can accelerate development timelines and support the scalable delivery of next-generation therapies.
